Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

November 17, 2026 by Alan Khadavi

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

Low-dose naltrexone, often called LDN, has attracted interest as a possible treatment for mast cell activation syndrome (MCAS). Some patients report feeling better while taking it, but the research remains limited.

LDN is not FDA-approved for MCAS, and it is not an established first-line treatment. Understanding what is known—and what remains uncertain—can help patients have an informed discussion with their allergist.

What Is MCAS?

Mast cells are immune cells that release chemicals such as histamine during allergic reactions. In MCAS, episodes of mast cell activation cause symptoms in multiple parts of the body. These may include flushing, hives, swelling, abdominal cramping, diarrhea, wheezing, or a drop in blood pressure.

Diagnosis requires more than a list of symptoms. Accepted criteria include recurrent episodes affecting multiple organ systems, laboratory evidence of increased mast cell mediator release during an episode, and improvement with treatment directed at these chemicals or cells. Other conditions that can cause similar symptoms also need to be considered.

Fatigue, brain fog, and food intolerances alone do not establish an MCAS diagnosis.

What Is Low-Dose Naltrexone?

Naltrexone is a prescription medicine that blocks opioid receptors. At standard doses, it is used to treat alcohol use disorder and help prevent relapse to opioid use after detoxification.

“Low-dose naltrexone” refers to much smaller doses used off-label for other conditions. Off-label means that the FDA has not approved that particular use.

LDN is often prepared by a compounding pharmacy. There is no FDA-approved LDN product specifically for MCAS and no validated MCAS dosing schedule.

Why Is LDN Being Considered for MCAS?

Researchers have proposed that low doses of naltrexone might affect inflammatory signaling and the body’s natural opioid system. One theory involves toll-like receptor 4, a protein involved in immune signaling.

However, these proposed effects have not been established as an effective treatment mechanism in people with MCAS. Describing LDN as a proven “mast cell stabilizer” or a medicine that “resets the immune system” goes beyond the available evidence.

What Does the Research Show?

The evidence for LDN in MCAS comes mainly from case reports and observational studies rather than rigorous, placebo-controlled trials.

A published case report described improvement in a patient with MCAS and postural orthostatic tachycardia syndrome (POTS) who received LDN, intravenous immunoglobulin, and antibiotics. Because several treatments were used, the overall improvement cannot be attributed to LDN alone.

A 2025 questionnaire study also found that some patients with an MCAS diagnosis reported benefit from LDN. These findings are worth studying, but self-reported treatment responses cannot establish that a medicine works. Differences in diagnosis, other treatments, symptom fluctuations, and expectations can influence the results.

At present, the evidence does not establish who is most likely to benefit, the best dose, or whether LDN prevents serious mast cell reactions.

Where Does LDN Fit Into MCAS Treatment?

Usual management focuses on identifying relevant triggers and controlling the effects of mast cell chemicals. Depending on the patient’s symptoms, treatment may include antihistamines, cromolyn, or leukotriene-targeting medicines. Specialists may consider other options for selected patients with persistent symptoms.

LDN should not replace these treatments or a prescribed emergency plan. If it is considered after usual treatments have been reviewed, the discussion should clearly address its uncertain benefit, medication interactions, and how improvement will be measured.

What Are the Side Effects and Safety Concerns?

Reported side effects of LDN include vivid dreams, trouble sleeping, nausea, dizziness, and stomach upset. “Low dose” does not mean risk-free, and long-term safety specifically in MCAS is not well established.

Opioid interactions are especially important. Naltrexone can interfere with opioid pain medicines and can trigger withdrawal in someone who is physically dependent on opioids. Relevant medicines include tramadol, codeine, hydrocodone, oxycodone, methadone, and buprenorphine. Do not stop an opioid or start LDN on your own; the prescriber must determine whether and when treatment can be started safely.

Tell surgeons, dentists, and emergency clinicians if you take naltrexone because it can affect pain-control options. Never take extra opioids to try to overcome its blocking effect.

Your clinician should also review liver or kidney disease, pregnancy or breastfeeding, other medicines, and any known reactions to the ingredients in a compounded preparation. Yellowing of the eyes or skin, dark urine, or significant abdominal pain warrants prompt medical review.

How Should a Treatment Trial Be Evaluated?

Before starting, agree with the prescriber on the symptoms being targeted and when treatment will be reassessed. A symptom diary can help track daily function, flare frequency, and side effects.

Persistent symptoms deserve reassessment rather than automatic dose increases. Improvement while taking LDN does not, by itself, confirm MCAS.

Can LDN Treat an Emergency Reaction?

No. LDN is not a rescue medicine for anaphylaxis.

If you develop sudden throat swelling, trouble breathing, fainting, or a rapidly worsening allergic reaction, use prescribed epinephrine promptly and call 911. Do not wait for LDN or an antihistamine to work.

An Individualized Decision, Not a Proven Solution

LDN remains an off-label option with uncertain effectiveness for MCAS. Some patients report benefit, but stronger studies are needed before it can be recommended routinely. A careful diagnosis, an appropriate symptom-control plan, and a clear emergency plan remain the foundation of care.

MCAS Treatment: Medication Options for Mast Cell Activation Syndrome

Mast Cell Activation Syndrome (MCAS): Fact & Fiction

How We Diagnose Mast Cell Activation Syndrome (MCAS): An Allergist’s Perspective

Filed Under: Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page